Status:
COMPLETED
Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude
Lead Sponsor:
University of Zurich
Conditions:
Obstructive Sleep Apnea Syndrome
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to investigate the effect of acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altit...
Eligibility Criteria
Inclusion
- Obstructive sleep apnea syndrome, successfully on CPAP therapy
- Residence at low altitude (\<800m)
- Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.
- \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP
Exclusion
- Sleep disorders other than OSA.
- More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.
- Any lung disease, pulmonary hypertension.
- Chronic rhinitis.
- Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
- Internal, neurologic or psychiatric disease that interfere with sleep quality.
- Previous intolerance to moderate or low altitude (\<2600m).
- Exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00714740
Start Date
June 1 2008
End Date
December 1 2008
Last Update
May 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pulmonary Division, University Hospital Zurich
Zurich, Switzerland, CH-8091